MicroPort® Makes the List of Top 20 Companies with Outstanding Contribution to Pudong New Area's Scientific and Technological Innovation in 2018

Shanghai, China – On April 2, 2019, the Award Ceremony for Companies with Outstanding Contribution to Pudong New Area’s Economy in 2018 was held at Shanghai International Convention Center. Officials from the Communist Party Committee, Government, Standing Committee of the People’s Congress and CPPCC Committee of Pudong New Area attended the ceremony. Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) was named as Top 20 Companies with Outstanding Contribution to Pudong New Area’s Scientific and Technological Innovation.

 

In 2018, Pudong New Area’s achievements were inspiring: Its GDP surpassed 1 trillion yuan, with the gross industrial output, total merchandise sales and foreign trade (import and export) surpassing 1 trillion yuan, 4 trillion yuan and 2 trillion yuan respectively; Its strategic emerging industries accounted for over 40% of the gross industrial output; It was home to 45%, 53% and 65% of all the Shanghai-based regional headquarters of multi-national corporations, overseas-funded R&D centers and overseas licensed financial institutions respectively. Mr. Yingwei Hang, who is Deputy Secretary-General of Shanghai Municipal Government, Deputy Party Secretary of Pudong New Area and Head of Pudong New Area Government, said that Pudong would try to drive a high-quality development, comprehensively deepen the building of Scientific and Technological Innovation Center, continuously promote “Four Brands”, and drive the deeply integrated development of “Five Centers”. Pudong’s new development engine will be fueled by the hard-core industries such as “Chinese Chips”, “Blue Sky Dreams”, “Innovative Drugs”, “Future Vehicles”, “Data Ports” and “Intelligent Manufacturing”, which will make Pudong a modern, high-end, intelligent highland for industries.

 

As a leading innovation-driven, high-end Chinese medical device group growing in Zhangjiang of Pudong, MicroPort® put a strong focus on independent innovation and consistently invests in research and development with high intensity. MicroPort® currently holds over 3,500 patents or patent applications (including 2,000 items overseas), and is a five-time winner of China National Science and Technology Progress Awards (including one award for corporate innovation platform models) and a multiple-time winner of the science and technology progress awards at province and ministry levels. As of December 2018, a total of 15 products have been granted entries into the Special Review and Approval Procedure for Innovative Medical Devices (the “Green Path”). MicroPort® respects and follows evidence-based medicine, with the clinical effects (expertise) of almost all of its core products and solutions having been published in the world’s mainstream scientific journals. Thus far, MicroPort® has released about 300 products to the market, covering 10 major business clusters, including interventional cardiology and structural heart, cardiac rhythm management and electrophysiology, orthopedics, endovascular, neurovascular and neuro science, diabetes and endocrine management, urology and women’s health, general surgery, surgical robotics, and artificial intelligence. The products have entered nearly 10,000 hospitals globally, covering Asia Pacific, Europe, and the Americas. We estimate that every 8 seconds a patient is being implanted with a MicroPort® manufactured device to save a life, improve the quality of a life, or create a new life.

 

MicroPort® was highly recognized by all walks of life for its R&D capacity of core technology and innovative products, while it was named as Top 20 Companies with Outstanding Contribution to Pudong New Area’s Scientific and Technological Innovation in 2018. In the future, MicroPort® will further deepen the building of a technological innovation system, which is market-oriented and integrates industries, universities and institutions. MicroPort® will also adhere to the rationales of innovation-led drive and steady operation and continuously improve and reinforce the product line to create more new products with independent intellectual property and help promote the development of China’s high-end medical device industry.